CD226 and non-small cell lung carcinoma: We next asked whether CD226 expression was also a determinant for clinical responses to atezolizumab, an anti-PD-L1 mAb, in patients with non-small cell lung carcinoma (NSCLC) (Fehrenbacher et al., 2016; Peters et al., 2017; Rittmeyer et al., 2017).